<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01562717</url>
  </required_header>
  <id_info>
    <org_study_id>0028022</org_study_id>
    <secondary_id>2011-004497-28</secondary_id>
    <nct_id>NCT01562717</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Ibuprofen in Patients With Ankle Injuries</brief_title>
  <official_title>A Randomised, Multicentre, Two-arm, Parallel Group, Double-blind, Placebo-controlled, Comparative Efficacy and Safety Clinical Study of Ibuprofen in Patients With Pain Related to Uncomplicated Ankle Injuries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orion Corporation, Orion Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the efficacy and safety of Ibuprofen in patients&#xD;
      with ankle injuries.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the study is to evaluate the efficacy and safety of Ibuprofen versus placebo&#xD;
      in patients for the treatment of pain related to uncomplicated ankle injuries.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: VAS</measure>
    <time_frame>Day 7</time_frame>
    <description>VAS pain score change over time from baseline to day 7</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy: VAS</measure>
    <time_frame>Day 3 and Day 7</time_frame>
    <description>Percentage VAS pain score change from baseline separately to day 3 and 7</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Ibuprofen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>3 times a day</description>
    <arm_group_label>Ibuprofen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>3 times a day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent obtained.&#xD;
&#xD;
          2. Male and female patients, age in the range of 18-45 years (inclusive).&#xD;
&#xD;
          3. Patients with pain related to uncomplicated ankle injuries (in case of doubt whether&#xD;
             it is complicated an X-ray should be taken).&#xD;
&#xD;
          4. Pain related to ankle injuries is scored as moderate or severe by the patient and the&#xD;
             injury is less than 24 hours old.&#xD;
&#xD;
          5. Patients with normal or clinically non-significant findings as determined by baseline&#xD;
             history, physical examination and vital signs (blood pressure, heart rate and axillary&#xD;
             temperature).&#xD;
&#xD;
          6. Comprehension of the nature and purpose of the study and compliance with the protocol&#xD;
             requirements.&#xD;
&#xD;
          7. Negative urine pregnancy test (for females only).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known hypersensitivity to aspirin or any non-steroidal anti-inflammatory drugs&#xD;
             (NSAID).&#xD;
&#xD;
          2. Known history of asthma.&#xD;
&#xD;
          3. Known history of gastric or peptic ulcer or bleeding.&#xD;
&#xD;
          4. Known history of malignancy or other serious diseases.&#xD;
&#xD;
          5. Known history of skin allergy.&#xD;
&#xD;
          6. Known history of cardiac, renal or hepatic insufficiency.&#xD;
&#xD;
          7. Presence of bruises or rash on the skin of ankle.&#xD;
&#xD;
          8. Presence of skin lesions like eczema or psoriasis.&#xD;
&#xD;
          9. Arthritis in the same joint.&#xD;
&#xD;
         10. Alcohol use during the study period or within 48 hours before the study enrolment.&#xD;
&#xD;
         11. Patients judged unable to use the VAS for pain reliably&#xD;
&#xD;
         12. Locally applied NSAID to the painful region/area of study or oral use of NSAID or&#xD;
             other analgesics 48 hours before the study enrolment.&#xD;
&#xD;
         13. Other pain killers than rescue medication to be taken during the study.&#xD;
&#xD;
         14. Recurrent sprain at the same joint during the last 6 months.&#xD;
&#xD;
         15. Anticoagulant therapy.&#xD;
&#xD;
         16. Physiotherapy during study period.&#xD;
&#xD;
         17. Open wounds, infected skin or fracture.&#xD;
&#xD;
         18. Any other condition that in the opinion of the investigator would interfere with the&#xD;
             evaluation of the results or constitute a health risk for the patient.&#xD;
&#xD;
         19. Pregnant or lactating females.&#xD;
&#xD;
         20. Participation in a drug or device study within 90 days before the study enrolment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juha-Pekka Kaukonen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Terveystalo Lahti</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Terveystalo Lahti</name>
      <address>
        <city>Lahti</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>March 22, 2012</study_first_submitted>
  <study_first_submitted_qc>March 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2012</study_first_posted>
  <last_update_submitted>May 7, 2013</last_update_submitted>
  <last_update_submitted_qc>May 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ankle Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

